| 05.04.22 | AstraZeneca sues Mylan after securing Symbicort patent; Zosano suspends migraine patch program

Laden...

2 jaren geleden

Html
Tekst

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

Lipid-based drug delivery systems have found widespread acceptance for development of drug products containing APIs posing developability challenges for formulators. This is evidenced by the significant numbers of FDA approved drug products that have been formulated using lipid-based formulations when a bioavailability-enhancing technology is required. Download to learn more.

Today's Rundown

AstraZeneca sues Mylan after securing fresh delivery patent on Symbicort No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program Bexson expands on-body ketamine delivery work into mental health Opiant beats path to FDA after nasal overdose drug matches Narcan 'The Top Line' podcast: Pharma advertising shifts gears and Novartis taps a surprising M&A czar, plus this week's headlines

Featured Story

AstraZeneca sues Mylan after securing fresh delivery patent on Symbicort

By Nick Paul Taylor

AstraZeneca has opened another front in its effort to protect its respiratory disease drug Symbicort from generic competition, securing a patent and immediately following up with a lawsuit against Mylan and Kindeva Drug Delivery.

Webinar Downlaod: The Faster Path From Pre-Filled Syringe to Auto-Injector

When transitioning from a traditional pre-filled syringe to an auto-injector, it’s important your manufacturing and device partners work together to help get your product to market, faster. Watch this webinar where Ypsomed and Catalent Biologics discuss integrated approaches to do just that. View Now.

No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program

By Nick Paul Taylor

Zosano Pharma’s headaches are intensifying. With the FDA again knocking back its transdermal migraine patch, the biotech has suspended its M207 program and made more layoffs to preserve its dwindling cash reserves.

Bexson expands on-body ketamine delivery work into mental health

By Nick Paul Taylor

Watch out Johnson & Johnson, Bexson Biomedical is expanding its on-body ketamine delivery program to mental health conditions including treatment-resistant depression. Bexson originally began working with drug delivery partner Stevanato on pain programs but is now branching out.

Opiant beats path to FDA after nasal overdose drug matches Narcan

By Nick Paul Taylor

Opiant Pharmaceuticals’ opioid overdose drug candidate has held its own against nasal naloxone in a trial of healthy volunteers, giving the company the data it needs to file for approval in the second half of the year.

'The Top Line' podcast: Pharma advertising shifts gears and Novartis taps a surprising M&A czar, plus this week's headlines

By Teresa Carey

This week The Top Line podcast discusses pharma's ad spending for 2021, an intriguing executive move at Novartis and more.

Article Download: Formulation Strategies When Transitioning From Vial to PFS

Prefilled syringes (PFS) can help cut manufacturing and product costs and offers significant benefits to the physician and patient. Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Download Now.